Trump's pledge to unleash oil and gas benefits stocks, specifically involving Bio-Rad Laboratories.
1 report, 1 independent
Updated Aug 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Trump's pledge to unleash oil and gas benefits stocks, specifically involving Bio-Rad Laboratories.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Bio-Rad Laboratories
American life science research firm
- Strategic acquisitions and product launches are driving growth for Bio-Rad Laboratories in the life science ddPCR and clinical diagnostics markets.
- Bio-Rad Laboratories is applying digital PCR technology through current partnerships, including Biodesix, Gencove, Insight Molecular, and Stilla Technologies.
Related events
- Trump's pledge to unleash oil and gas benefits stocks, specifically impacting Mirum Pharmaceuticals.
- Trump's pledge to unleash American oil and gas benefits certain stocks, impacting EyePoint Pharmaceuticals.
- Trump's pledge to unleash oil and gas is reported to benefit stocks, involving Stantec.
- Trump's pledge to unleash oil and gas is reported to benefit stocks, involving Amedisys, Inc.
- Trump's pledge benefits US oil and gas stocks, leading to scrutiny regarding the financial viability of both companies.
Coverage
Newest first; wire copies grouped- Simply Wall St.Bio-Rad Laboratories Second Quarter 2025 Earnings: EPS: US$11.67 (vs US$76.26 loss in 2Q 2024) Revenue: US$651.6m (up 2.1% from 2Q 2024). Net income: US$317.8m (up from US$2.17b loss in 2Q 2024). Pro